- Home
- AUPH vs ATRO Comparison
AUPH vs ATRO Comparison
Compare AUPH & ATRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- ATRO
- Stock Information
- Founded
- AUPH 1993
- ATRO 1968
- Country
- AUPH Canada
- ATRO United States
- Employees
- AUPH N/A
- ATRO N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- ATRO Military/Government/Technical
- Sector
- AUPH Health Care
- ATRO Industrials
- Exchange
- AUPH Nasdaq
- ATRO Nasdaq
- Market Cap
- AUPH 999.8M
- ATRO 844.1M
- IPO Year
- AUPH 1999
- ATRO N/A
- Fundamental
- Price
- AUPH $7.85
- ATRO $29.57
- Analyst Decision
- AUPH Strong Buy
- ATRO Hold
- Analyst Count
- AUPH 2
- ATRO 1
- Target Price
- AUPH $11.50
- ATRO $21.00
- AVG Volume (30 Days)
- AUPH 1.1M
- ATRO 533.9K
- Earning Date
- AUPH 05-12-2025
- ATRO 05-06-2025
- Dividend Yield
- AUPH N/A
- ATRO N/A
- EPS Growth
- AUPH N/A
- ATRO N/A
- EPS
- AUPH 0.27
- ATRO N/A
- Revenue
- AUPH $247,295,000.00
- ATRO $816,288,000.00
- Revenue This Year
- AUPH $11.86
- ATRO $7.69
- Revenue Next Year
- AUPH $24.96
- ATRO $6.12
- P/E Ratio
- AUPH $29.71
- ATRO N/A
- Revenue Growth
- AUPH 29.20
- ATRO 13.73
- 52 Week Low
- AUPH $4.98
- ATRO $14.13
- 52 Week High
- AUPH $10.67
- ATRO $26.63
- Technical
- Relative Strength Index (RSI)
- AUPH 44.68
- ATRO 74.85
- Support Level
- AUPH $7.89
- ATRO $23.25
- Resistance Level
- AUPH $8.49
- ATRO $28.39
- Average True Range (ATR)
- AUPH 0.30
- ATRO 1.07
- MACD
- AUPH -0.02
- ATRO 0.80
- Stochastic Oscillator
- AUPH 36.95
- ATRO 93.17
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About ATRO Astronics Corporation
Astronics Corp supplies products to the aerospace, defense, and electronics industries. The company has two reportable segments namely Aerospace and Test Systems. The aerospace segment serves three primary markets: military, commercial transport, and General Aviation. The Test Systems segment serves the aerospace, defense, and semiconductor markets. The company generates a majority of its revenue from the Aerospace segment. Geographically, it generates a majority of its revenue from the United States.